Mankind Pharma Analyst Review May 2026

This Mankind Pharma analyst review for May 2026 covers the key data investors need for MANKIND at its current price of Rs 2,493.80. Mankind Pharma (NSE: MANKIND) is one of India’s largest branded pharma companies by prescriptions with a market capitalisation of approximately Rs 1,02,000 crore. The analyst consensus target of Rs 3,000 implies meaningful upside, and this Mankind Pharma analyst review examines technical levels, business performance, valuation, and key risks that will determine whether MANKIND achieves that target through FY27.

Click Here – Get Free Investment Predictions

Mankind Pharma Company Snapshot May 2026

Mankind Pharma holds the No.1 position by prescription volumes in India, driven by mass-market brands like Manforce, Moxikind-CV, Glimestar, and Dydroboon. The company has a strong rural and semi-urban doctor outreach network. The table below summarises the key data referenced in this Mankind Pharma analyst review.

Parameter	Value
NSE Ticker	MANKIND
Sector	Pharmaceuticals – Branded Generics
CMP (May 2026)	Rs 2,493.80
52 Week High	Rs 2,716.50
52 Week Low	Rs 1,909.70
Market Cap	Rs 1,02,000 Crore
Trailing P/E	32x
Analyst Consensus Target	Rs 3,000
Bull Case Target	Rs 3,700
Bear Case Target	Rs 2,200

Analyst Insight in This Mankind Pharma Analyst Review

Associate Director Kunal Singla suggests watching Mankind Pharma closely in May 2026. At Rs 2,493.80, Kunal Singla flags Pharmaceuticals – Branded Generics sector dynamics as the primary driver for MANKIND’s near-term price action. He notes support in the Rs 1948 to Rs 2369 zone and flags any sustained close above Rs 2643 as a positive signal worth tracking. Kunal Singla’s perspective on Mankind Pharma adds professional analysis to this Mankind Pharma analyst review and is not a buy recommendation.

Technical Analysis in This Mankind Pharma Analyst Review

At Rs 2,493.80, MANKIND is trading within its 52-week band of Rs 1,909.70 to Rs 2,716.50. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1948 to Rs 2369 band while resistance is seen in the Rs 2643 to Rs 2747 zone. A sustained move above Rs 2643 could open the path toward the analyst consensus target of Rs 3,000.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1948 to Rs 2369 – investors tracking this Mankind Pharma analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for MANKIND.
• Resistance Zone: Rs 2643 to Rs 2747 – a sustained close above Rs 2643 would be a positive breakout signal worth flagging in this Mankind Pharma analyst review.
• Medium-Term Target: The analyst consensus of Rs 3,000 represents the base-case upside scenario identified in this Mankind Pharma analyst review.

Business Segment Analysis

Branded Generics (Cardiology, Anti-infectives, Gynaecology)

This is the primary revenue and margin driver for Mankind Pharma, directly supporting the earnings trajectory toward the consensus target of Rs 3,000.

Consumer Healthcare (Manforce, Prega News, Gas-O-Fast)

This segment adds scale and diversification to Mankind Pharma’s business model and is a meaningful EPS contributor through FY27 and FY28.

International Generics (Emerging Markets)

This represents the medium-term growth frontier for Mankind Pharma and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Mankind Pharma Analyst Review

At Rs 2,493.80, Mankind Pharma trades at a trailing P/E of 32x. This Mankind Pharma analyst review presents three valuation scenarios: a bull case of Rs 3,700 on strong earnings delivery and sector tailwinds, a base case of Rs 3,000 at analyst consensus, and a bear case of Rs 2,200 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Mankind Pharma analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 3,700	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 3,000	Moderate growth, analyst consensus estimate
Bear Case	Rs 2,200	Earnings miss or macro headwinds

Trade Outlook for Mankind Pharma

Based on the technical and fundamental analysis in this Mankind Pharma analyst review, investors might watch MANKIND near the support zone of Rs 1948 to Rs 2369 for potential opportunities. A flag above Rs 2643 could suggest improving momentum toward Rs 3,000. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Mankind Pharma in FY27

A well-rounded Mankind Pharma analyst review must assess downside risks. Key risks for Mankind Pharma include a macro slowdown affecting Pharmaceuticals – Branded Generics sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in MANKIND.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Mankind Pharma Analyst Review Verdict for 2026

This Mankind Pharma analyst review concludes that at Rs 2,493.80, MANKIND offers a defined risk-reward with a consensus target of Rs 3,000. The 52-week range of Rs 1,909.70 to Rs 2,716.50 provides context on the current entry point. Use this Mankind Pharma analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on MANKIND.

Frequently Asked Questions: Mankind Pharma Analyst Review 2026

What is the analyst target for Mankind Pharma in 2026?

The analyst consensus target is Rs 3,000, with a bull case of Rs 3,700 and a bear case of Rs 2,200. Monitor Q1 FY27 earnings for confirmation as highlighted in this Mankind Pharma analyst review.

Is Mankind Pharma a good investment at Rs 2,493.80?

At Rs 2,493.80 with a P/E of 32x and a consensus target of Rs 3,000, this Mankind Pharma analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Branded Generics sector. Always consult a SEBI-registered advisor before investing.

What is Mankind Pharma’s 52-week high and low?

The 52-week high is Rs 2,716.50 and the 52-week low is Rs 1,909.70. At Rs 2,493.80, MANKIND is positioned within this range as noted in this Mankind Pharma analyst review.

What are the key risks for Mankind Pharma?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Branded Generics sector as assessed in this Mankind Pharma analyst review.

Where can I track live data for Mankind Pharma?

Track Mankind Pharma’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Mankind Pharma analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.